Atlas Trials

Ascending Dose and Exploratory Expansion Study of DS-3032b, an Oral MDM2 Inhibitor, in Subjects With Relapsed and/or Refractory Multiple Myeloma

Clinical trial NCT02579824 · TERMINATED

Trial details

NCT number
NCT02579824
Sponsor
M.D. Anderson Cancer Center
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
Myeloma
Start date
2016-08-30
Primary completion
2019-11-07
Enrollment
14

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.